Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma

Cancer Letters

Volumn 157, Issue 1, 2000, Pages 99-103

  Busquets, Sílvia ^a   Alvarez, Belén ^a   Van Royen, Martin ^a   Carbó, Neus ^a   López Soriano, Francisco J ^a   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer cachexia; Interleukin 1; Tumour necrosis factor

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; GLUCOSE; LACTIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; ASCITES HEPATOMA; CACHEXIA; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; WEIGHT REDUCTION;

ADIPOSE TISSUE; ALANINE; ANIMALS; ANOREXIA; BLOOD GLUCOSE; CACHEXIA; CELL DIVISION; FEMALE; INTERLEUKIN-1; LACTIC ACID; LIVER NEOPLASMS, EXPERIMENTAL; MUSCLE, SKELETAL; ORGAN SIZE; PROTEIN SYNTHESIS INHIBITORS; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; SARCOMA, YOSHIDA; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

ANIMALIA;

EID: 0034739328     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00476-6     Document Type: Article

References (33)

1. Warren S. The immediate cause of death in cancer. Am. J. Med. Sci. 184:1932;610-613.
2. Argilés J.M., Alvarez B., López-Soriano F.J. The metabolic basis of cancer cachexia. Med. Res. Rev. 17:1997;477-498.
3. De Wys W.D. Management of cancer cachexia. Semin. Oncol. 12:1985;452-460.
4. Harvey K.B., Bothe A., Blackburn G.L. Nutritional assessment and patient outcome during oncological therapy. Cancer. 43:1979;2065-2069.
5. Nixon D.W., Heymsfield S.B., Kutner M.M., Ansley J., Lawson D.H. Protein-caloric undernutrition in hospitalized cancer patients. Am. J. Med. 68:1980;491-497.
6. Argilés J.M., García-Martínez C., Llovera M., López-Soriano F.J. The role of cytokines in muscle wasting: its relation with cancer cachexia. Med. Res. Rev. 12:1992;637-652.
7. Adams R., Victor M. Asthenia. Victor M., Adams R. Principles of Neurology. 1981;341-345 McGraw-Hill, New York.
8. Evans R.D., Argilés J.M., Williamson D.H. Metabolic effects of tumour necrosis factor-α (cachectin) and interleukin-1. Clin. Sci. 77:1989;357-364.
9. Argilés J.M., López-Soriano F.J. Catabolic proinflammatory cytokines. Curr. Opin. Clin. Nutr. Metab. Care. 1:1998;241-251.
10. Yamamoto N., Sakai F., Yamazaki H., Nakahara K., Okuhara M. Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur. J. Pharmacol. 314:1996;137-142.
11. Tessitore L., Bonetti G., Baccino F.M. Early development of protein metabolic perturbations in the liver and skeletal muscle of tumour-bearing rats. Biochem. J. 241:1987;153-159.
12. Hirano T. Cytokine suppressive agent improves survival rate in rats with acute pancreatitis of closed duodenal loop. J. Surg. Res. 81:1999;224-229.
13. Tessitore L., Costelli P., Bonetti G., Baccino F.M. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch. Biochem. Biophys. 306:1993;52-58.
14. Eggstein M., Kreutz F.H. new method for the determination of neutral fats in blood serum and tissues. Klin. Wochenschr. 44:1966;262-267.
15. Hohorst H.J., Kreutz F.H., Bücher T. On the metabolite content and the metabolite concentration in the liver of the rat. Biochem. Z. 332:1959;18-46.
16. Slein M.W. D-Glucose determination with hexokinase and glucose-6-phosphate dehydrogenase. Bergmeyer H.U. Methods of Enzymatic Analysis. 1963;117-123 Academic Press, New York.
17. Williamson D.H. L-Alanine determination with alanine dehydrogenase. Bergmeyer H.U. Methods of Enzymatic Analysis. 1974;1679-1682 Academic Press, New York.
18. Ward A., Clissold S.P. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 34:1987;50-97.
19. Balazs C., Kiss E. Immunological aspects of the effect of pentoxifylline (Trental). Acta Microbiol. Immunol. Hung. 41:1994;121-126.
20. Combaret L., Ralliere C., Taillandier D., Tanaka K., Attaix D., anipulation M. of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol. Biol. Rep. 26:1999;95-101.
21. Goldberg R.M., Loprinzi C.L., Mailliard J.A., O'Fallon J.R., Krook J.E., Ghosh C., Hestorff R.D., Chong S.F., Reuter N.F., Shanahan T.G. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 13:1995;2856-2859.
22. Dezube B.J., Sherman M.L., Fridovich-Keil J.L., Allen-Ryan J., Pardee A.B. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol. Immunother. 36:1993;57-60.
23. Breuille D., Farge M.C., Rose F., Arnal M., Attaix D., Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am. J. Physiol. 265:1993;E660-E666.
24. Landman D., Sarai A., Sathe S.S. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin. Infect. Dis. 18:1994;97-99.
25. Semmler J., Wachtel H., Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15:1993;409-413.
26. Wachtel H. Potential antidepressant activity of rolipram and other selective adenosine 3′,5′-monophosphate phosphodiesterase inhibitors, Neuropharmacology. 22:1983;267-272.
27. Zeller E., Stief H.J., Pflug B., Sastre-Hernández M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 17:1984;188-190.
28. Badger A.M., Olivera D.L., Esser K.M. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxic shock. Circ. Shock. 44:1994;188-195.
29. Jurasinski C.V., Kilpatrick L., Vary T.C. Amrinone prevents muscle protein wasting during chronic sepsis. Am. J. Physiol. 268:1995;E491-E500.
30. Costelli P., Carbó N., Tessitore L., Bagby G.J., López-Soriano F.J., Argilés J.M., Baccino F.M. Tumour necrosis factor-α mediates changes in tissue protein turnover in a rat cachexia model. J. Clin. Invest. 92:1993;2783-2789.
31. Yamamoto N., Kawamura I., Nishigaki F., Tsujimoto S., Naoe Y., Inami M., Elizabeth L., Manda T., Shimomura K. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon-26-induced cachexia in mice. Anticancer Res. 18:1998;139-144.
32. Argilés J.M., Azcón-Bieto J. The metabolic environment of cancer. Mol. Cell. Biochem. 81:1988;3-17.
33. Yamamoto N., Sakai F., Yamazaki H., Sato N., Nakahara K., Okuhara M. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur. J. Pharmacol. 327:1997;169-174.